Condition: Breast Cancer · Sponsor: Cellectar Biosciences, Inc.
The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are: * What dose and regimen should be used in future trials of CLR 125 in patients with advanced triple negative breast cancer. * What side effects do participants have when taking CLR 125. Participants will: * Have CLR 125 administered via infusion 4 times each cycle; repeated every 8 weeks. * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or new medications. Some participants may also receive one dose of CLR 131 to evaluate the amount of radiation delivered to various organs and to the tumor. These participants will: * Have 4 scans completed over 2 weeks * Have blood drawn 6 times over 2 weeks.
This description comes directly from the study's public registry record.
Kate Oliver · 608-441-8120 · clinical@cellectar.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Florida | Jacksonville, Florida, United States | Recruiting |
| United Theranostics | Glen Burnie, Maryland, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| United Theranostics | Princeton, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07311993